Results 101 to 110 of about 53,519 (232)

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley   +15 more
wiley   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra   +5 more
wiley   +1 more source

Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group

open access: yesJournal of Paediatrics and Child Health, EarlyView.
ABSTRACT Background Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives To develop a clinical practice guideline for the use of asparaginase products in the Australasian context.
Matthew J. O'Connor   +15 more
wiley   +1 more source

A rare case of Philadelphia-positive (P210BCR-ABL1) T-cell acute lymphoblastic leukemia/lymphoma associated with minimal residual disease persistence after intensive chemotherapeutic approaches

open access: yesLeukemia Research Reports
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a rare and aggressive leukemia. Philadelphia chromosome-positive cytogenetic abnormality is most common in CML.
Shruti Shah   +4 more
doaj   +1 more source

Challenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023–2024 Outbreak in Argentina

open access: yesTransplant Infectious Disease, EarlyView.
During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez   +16 more
wiley   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

open access: yesTransplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford   +32 more
wiley   +1 more source

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation

open access: yesTransfusion, EarlyView.
Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these ...
Anna Söderström   +8 more
wiley   +1 more source

Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route,
Rachel Hanford   +5 more
wiley   +1 more source

Case Report: T‐Lymphoblastic Leukemia in a Dog With Erythrophagia

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT A 2‐year‐old male German Shepherd dog was presented with progressive weight loss, lethargy, and hyporexia. Hematologic analysis revealed a moderate macrocytic normochromic anemia and moderate thrombocytopenia. Additionally, a pronounced leukocytosis was observed, characterized by 33% large lymphoid cells, marked neutrophilia with a significant
Francisca B. Lang   +7 more
wiley   +1 more source

Analysis of ADVIA Myeloperoxidase Cytogram LUC Angle Does Not Distinguish Acute Myeloid Leukemia From Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Dogs

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT Background Acute myeloid leukemia (AML) is difficult to distinguish from lymphoblastic leukemia or lymphoma (LL) on morphologic features alone. Therapeutic approaches for AML versus LL differ, and immediate therapy is often needed due to patient illness and rapid disease progression.
Mayzie Miller   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy